BR112018073549A2 - tratamento de lesões de pele - Google Patents

tratamento de lesões de pele

Info

Publication number
BR112018073549A2
BR112018073549A2 BR112018073549-3A BR112018073549A BR112018073549A2 BR 112018073549 A2 BR112018073549 A2 BR 112018073549A2 BR 112018073549 A BR112018073549 A BR 112018073549A BR 112018073549 A2 BR112018073549 A2 BR 112018073549A2
Authority
BR
Brazil
Prior art keywords
skin injury
injury treatment
formula
treatment
tautomers
Prior art date
Application number
BR112018073549-3A
Other languages
English (en)
Other versions
BR112018073549A8 (pt
Inventor
Fabbro Doriano
Hebeisen Paul
Hillmann-Wuellner Petra
Stuetz Anton
T. Seykora John
Beaufils Florent
Original Assignee
Piqur Therapeutics Ag
The Trustees Of The University Of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piqur Therapeutics Ag, The Trustees Of The University Of Pennsylvania filed Critical Piqur Therapeutics Ag
Priority claimed from PCT/EP2017/025137 external-priority patent/WO2017198347A1/en
Publication of BR112018073549A2 publication Critical patent/BR112018073549A2/pt
Publication of BR112018073549A8 publication Critical patent/BR112018073549A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

a presente invenção refere-se a um composto da fórmula (i), (i) com a condição de que pelo menos um dentre r1 e r2 é uma morfolinila de fórmula ii; (ii) e profármacos, metabólitos, tautômeros, solvatos e sais farmaceuticamente aceitáveis dos mesmos, para uso na prevenção ou no tratamento de uma lesão de pele em um sujeito.
BR112018073549A 2016-05-18 2017-05-17 Uso de inibidores seletivos e específicos de mtor e/ou de inibidores duplos de pi3k/mtor, e composição farmacêutica BR112018073549A8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662338111P 2016-05-18 2016-05-18
US62/338,111 2016-05-18
EP17151843 2017-01-17
EP17151843.4 2017-01-17
PCT/EP2017/025137 WO2017198347A1 (en) 2016-05-18 2017-05-17 Treatment of skin lesions

Publications (2)

Publication Number Publication Date
BR112018073549A2 true BR112018073549A2 (pt) 2019-03-19
BR112018073549A8 BR112018073549A8 (pt) 2023-01-10

Family

ID=65463390

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018073549A BR112018073549A8 (pt) 2016-05-18 2017-05-17 Uso de inibidores seletivos e específicos de mtor e/ou de inibidores duplos de pi3k/mtor, e composição farmacêutica

Country Status (9)

Country Link
US (2) US10993947B2 (pt)
JP (3) JP7118509B2 (pt)
KR (1) KR102483630B1 (pt)
CN (1) CN109414415B (pt)
BR (1) BR112018073549A8 (pt)
IL (1) IL263076B (pt)
MX (1) MX2018014167A (pt)
RU (1) RU2018140001A (pt)
ZA (1) ZA201807325B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61655B1 (sr) * 2016-05-18 2021-04-29 Torqur Ag Lečenje neuroloških poremećaja
CN111315384A (zh) * 2017-11-23 2020-06-19 皮奎尔治疗公司 皮肤病的治疗

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2007095092A2 (en) * 2006-02-09 2007-08-23 Alba Therapeutics Corporation Formulations for a tight junction effector
CN101711241A (zh) * 2007-02-06 2010-05-19 诺瓦提斯公司 Pi3-激酶抑制剂和它们的使用方法
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2012099968A1 (en) * 2011-01-19 2012-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for treating skin cancer associated diseases
US9481670B2 (en) 2011-01-25 2016-11-01 Sphaera Pharma Pte. Ltd. Triazine compounds
US20140309221A1 (en) * 2011-02-11 2014-10-16 Dana-Farber Cancer Institute, Inc. Method of inhibiting hamartoma tumor cells
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
WO2014090147A1 (zh) * 2012-12-14 2014-06-19 上海恒瑞医药有限公司 嘧啶类衍生物及其可药用盐、其制备方法及其在医药上的应用
US20150065431A1 (en) 2013-08-27 2015-03-05 Northwestern University Reducing cutaneous scar formation and treating skin conditions
CN103483345B (zh) * 2013-09-25 2016-07-06 中山大学 Pi3k激酶抑制剂、包含其的药物组合物及其应用
CN104557871B (zh) * 2013-10-28 2017-05-03 上海汇伦生命科技有限公司 具有螺环取代基的芳基吗啉类化合物，其制备方法和用途
BR112016023811B8 (pt) * 2014-04-22 2023-01-10 Piqur Therapeutics Ag Método para fabricação para derivados de triazina, pirimidina e piridina, seus intermediários e seus métodos de fabricação
JP2017516799A (ja) 2014-05-27 2017-06-22 アルミラル・ソシエダッド・アノニマＡｌｍｉｒａｌｌ， Ｓ．Ａ． 医薬用途
WO2016003902A1 (en) * 2014-06-30 2016-01-07 Baxter Corporation Englewood Managed medical information exchange
MA40933A (fr) 2014-11-11 2017-09-19 Piqur Therapeutics Ag Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
RS61655B1 (sr) 2016-05-18 2021-04-29 Torqur Ag Lečenje neuroloških poremećaja

Also Published As

Publication number Publication date
CN109414415B (zh) 2023-05-02
MX2018014167A (es) 2019-08-16
KR20190026668A (ko) 2019-03-13
US11918586B2 (en) 2024-03-05
IL263076A (en) 2018-12-31
IL263076B (en) 2022-02-01
JP7118509B2 (ja) 2022-08-16
ZA201807325B (en) 2019-08-28
KR102483630B1 (ko) 2023-01-02
RU2018140001A3 (pt) 2020-08-21
US20210361665A1 (en) 2021-11-25
JP7464645B2 (ja) 2024-04-09
BR112018073549A8 (pt) 2023-01-10
US20190290653A1 (en) 2019-09-26
JP2019515020A (ja) 2019-06-06
US10993947B2 (en) 2021-05-04
RU2018140001A (ru) 2020-06-18
JP2022088520A (ja) 2022-06-14
JP2024050600A (ja) 2024-04-10
CN109414415A (zh) 2019-03-01

Similar Documents

Publication Publication Date Title
CL2021000382A1 (es) Compuestos novedosos de sulfonamidaurea
BR112021009595A2 (pt) Terapia de combinação incluindo um inibidor de krasg12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cânceres
ECSP20069418A (es) Compuestos heterocíclicos como inmunomoduladores
UY37847A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
CO2019007810A2 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
CL2017001124A1 (es) Agentes inmunomoduladores
BR112018072570A2 (pt) piperidinas como inibidores de menina
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
BR112019006712A2 (pt) composto, composição farmacêutica, composição para uso no tratamento de uma doença, elemento implantável, e, dispositivo.
BR112018070859A2 (pt) degradantes da proteína de bet
BR112019002576A2 (pt) composto, medicamento¸ métodos para inibição de gcn2 em um mamífero e para a profilaxia ou tratamento de câncer em um mamífero, e, uso do composto ou um sal do mesmo
BR112022000019A2 (pt) Composto da fórmula, composição farmacêutica e método de tratamento de câncer
ECSP20030074A (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
BR112016015449A8 (pt) compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
BR112015026021A2 (pt) terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
BR112018011700A2 (pt) ?moduladores de canais de kv3 para tratar dor?
BR112018014675A2 (pt) novos derivados de cianoindolina substituída como inibidores de nik
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BR112019020421A8 (pt) Derivados de 2-oxo- tiazóis como inibidores de a2a e compostos para uso no tratamento de cânceres
BR112018070536A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
PH12020550583A1 (en) Use of riluzole prodrugs to treat ataxias
BR112023014973A2 (pt) Derivados de urolitina e métodos de uso dos mesmos
CO2022000270A2 (es) Inhibidores de enzimas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) ; TORQUR AG (CH)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]